Our data now indicate that the same is true for TNK2, since the significant reduction of cell surface EGFRs we observed by TNK2 silencing was accompanied by a parallel decrease in the migratory capacity of the breast cancer cells. This evidence concerns the gene TNK2 and breast cancer.